Matthew H. Kulke, MD

Zoltan Kohn Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Matthew Kulke MD is the Chief of Hematology/Oncology, Co-Director of the BU/BMC Cancer Center and Zoltan Kohn Professor at the Chobanian and Avedisian School of Medicine. Dr. Kulke is an internationally recognized for his work in the field of neuroendocrine tumors. He has led or co-led both early and late stage clinical trials leading to the development of telotristat ethyl, temozolomide, sunitinib, everolimus and peptide receptor radiotherapy for the treatment of neuroendocrine tumors. His work has additionally included characterization of neuroendocrine tumors at the molecular level, and has resulted in over 200 peer-reviewed publications.

Dr. Kulke received his undergraduate degree in molecular biology from Princeton University magna cum laude, and his medical degree with a thesis honors award from the University of California, San Francisco School of Medicine where he also was a Regent’s scholar and received a research training fellowship from the Howard Hughes Medical Institute. He performed his internship and residency at Brigham and Women’s Hospital, a medical oncology fellowship at Dana-Farber Cancer Institute, and received a Masters in Medical Science Degree from Harvard Medical School.

Prior to coming to Boston University he was a Professor of Medicine at Harvard Medical School and Director of the Neuroendocrine Tumor Program at Dana-Farber Cancer Institute. He has served as principal investigator for NCI cooperative group trials in both neuroendocrine tumors and pancreatic cancer, served as chair of the National Cancer Institute’s Neuroendocrine Tumor Clinical Trial Task Force, chair of the North American Neuroendocrine Tumor Society, and chair of the National Comprehensive Cancer Network’s neuroendocrine tumor guidelines committee.

Publications

  • Published 10/6/2025

    Lyons R, Qian F, Kulke MH, Pande A, Siddiqi OS. Case report of a transcatheter pulmonic valve-in-valve replacement through a bioprosthetic tricuspid valve in a patient with carcinoid heart disease. Eur Heart J Case Rep. 2025 Oct; 9(10):ytaf484. PMID: 41113393.

    Read at: PubMed

  • Published 3/10/2025

    Radwan A, Jani CT, Al Omari O, Patel M, Burns L, Mackay Z, Li L, Mahdaviani K, Davidson A, Weinberg J, Everett PC, Suzuki K, Mak KS, Kulke MH, Tapan U. The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients. Oncologist. 2025 Mar 10; 30(3). PMID: 39603266.

    Read at: PubMed

  • Published 1/17/2025

    Perez K, Kulke MH, Zheng H, Allen J, Clark J, Enzinger AC, Enzinger PC, Johnson BE, McCleary NJ, Parikh A, Patel A, Rubinson D, Yurgelun MB, Ramsey K, Johnson E, Graham C, Chan JA. A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors. Oncologist. 2025 Jan 17; 30(1). PMID: 39834129.

    Read at: PubMed

  • Published 9/16/2024

    Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, Ou FS, Dueck AC, Acoba J, Shergill A, Wolin EM, Halfdanarson TR, Konda B, Trikalinos NA, Tawfik B, Raj N, Shaheen S, Vijayvergia N, Dasari A, Strosberg JR, Kohn EC, Kulke MH, O'Reilly EM, Meyerhardt JA. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13; 392(7):653-665. PMID: 39282913.

    Read at: PubMed

  • Published 9/5/2024

    Lazzaro A, Zhao GQ, Kulke M. Diagnosis and Management of Parathyroid Carcinoma. Clin Pharmacol Ther. 2024 Dec; 116(6):1496-1505. PMID: 39234888.

    Read at: PubMed

View All 235 Publications:   View Full Profile in BUMC

Other Positions

  • Section Chief, Medicine
    Boston Medical Center
  • Co-Director, BU-BMC Cancer Center
    Boston University
  • Member, Evans Center for Interdisciplinary Biomedical Research
    Boston University

Websites

Education

  • University of California, San Francisco, MD
  • Harvard Medical School, MMS/MMSc
  • Princeton University, BA

View all profiles